{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:27:09Z","timestamp":1792427229975,"version":"4.5.0"},"reference-count":119,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Autologous stem cell transplantation (auto-SCT) has been the standard of care in eligible newly diagnosed multiple myeloma (MM) patients. Outcomes of patients with MM have improved significantly due to the advent of several novel drugs. Upfront use of these drugs in induction therapy has significantly increased the rate and depth of responses that have translated into longer remission and survival. This has now raised a debate regarding the role and relevance of auto-SCT in the management of myeloma. However, clinical trials have confirmed the utility of auto-SCT even in the era of novel drugs. Tandem auto-SCT followed by maintenance has shown a progression-free survival (PFS) benefit in high-risk MM, and hence can be considered in young and fit patients with high-risk disease. Auto-SCT has the advantages of resetting the bone marrow microenvironment, short-lived toxicity compared to the long-term physical and financial toxicities of continued chemotherapy in the absence of SCT, very low transplant-related mortality (TRM) in high volume centers, and providing longer disease-free survival when followed by maintenance therapy. Allogeneic SCT is one potentially curative option for MM, albeit with an increased risk of death due to high TRM. Strategies to modulate the graft-versus-host disease (GVHD) while maintaining or improving the graft-versus-myeloma (GVM) effect could place allogeneic SCT back in the treatment armamentarium of MM.<\/jats:p>","DOI":"10.3390\/cancers13040863","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T20:56:21Z","timestamp":1613681781000},"page":"863","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Role of Stem Cell Transplantation in Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-1025","authenticated-orcid":false,"given":"Srinivas","family":"Devarakonda","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-7099","authenticated-orcid":false,"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.seminoncol.2013.08.001","article-title":"Individualized therapy in multiple myeloma: Are we there?","volume":"40","author":"Girnius","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_3","first-page":"318","article-title":"Chemotherapy of previously untreated multiple myeloma patients: An analysis of recent treatment results","volume":"13","author":"Sporn","year":"1986","journal-title":"Semin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Koreth","year":"2007","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1158\/1078-0432.CCR-04-1106","article-title":"Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant","volume":"10","author":"Stewart","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CCO.0b013e328324bc04","article-title":"Stem cell transplantation for multiple myeloma","volume":"21","author":"Kumar","year":"2009","journal-title":"Curr. Opin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/bmt.2015.106","article-title":"High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma","volume":"50","author":"Wildes","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current Use and Trends in Hematopoietic Cell Transplantation in the United States","volume":"23","author":"Lee","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1182\/blood-2019-127166","article-title":"Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017","volume":"134","author":"Hayden","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jgo.2019.09.012","article-title":"Use of geriatric assessment in hematopoietic cell transplant","volume":"11","author":"Jayani","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","volume":"10","author":"Rosko","year":"2019","journal-title":"J. Geriatr. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_21","first-page":"2645","article-title":"Autologous hematopoietic stem-cell transplantation for multiple myeloma","volume":"360","author":"Philippe","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","article-title":"Autologous stem cell transplantation in multiple myeloma: Outcome in patients with renal failure","volume":"75","author":"Knudsen","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/bmt.2017.198","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A center for international blood and marrow transplant research analysis","volume":"52","author":"Mahindra","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bmt.2014.226","article-title":"Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure","volume":"50","author":"Bernard","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.leu.2401819","article-title":"Safety of autologous hematopoietic stem cell transplantation inpatients with multiple myeloma and chronic renal failure","volume":"14","author":"Tosi","year":"2000","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ejh.13101","article-title":"Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients\u2014DAUTOS Study of the Polish Myeloma Study Group","volume":"101","author":"Lewandowski","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomized, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2009.22.7389","article-title":"Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma","volume":"27","author":"Cavo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V126.23.393.393","article-title":"Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM 2013\u201304 trial","volume":"126","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"6","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"20","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2008.12.512","article-title":"Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation","volume":"15","author":"Kim","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00277-013-1911-1","article-title":"Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma","volume":"93","author":"Lee","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2011.051441","article-title":"Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease","volume":"97","author":"Lahuerta","year":"2012","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","article-title":"Multiple myeloma treated with high dose intravenous melphalan","volume":"66","author":"Selby","year":"1987","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.clml.2015.05.008","article-title":"BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma","volume":"15","author":"Veeraputhiran","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2141.2005.05641.x","article-title":"High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma:results of a randomised study","volume":"130","author":"Fenk","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.20294","article-title":"Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma","volume":"100","author":"Anagnostopoulos","year":"2004","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","article-title":"Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: A matched comparison to a melphalan-only approach","volume":"19","author":"Blanes","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_45","first-page":"399","article-title":"A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma","volume":"130","author":"Qazilbash","year":"2017","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bmt.2016.94","article-title":"A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy","volume":"51","author":"Martino","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hon.2546","article-title":"Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients","volume":"36","author":"Farag","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41409-019-0587-0","article-title":"High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma","volume":"54","author":"Mark","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_49","first-page":"398","article-title":"Bortezomib and high-dose Melphalan vs. high-dose melphalan as conditioning regimen before autologous stem cell transplantation in de novo multiple myeloma patients: A phase 3 study of the Intergroupe Francophone Du Myelome (IFM 2014\u201302)","volume":"130","author":"Roussel","year":"2017","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbmt.2017.03.007","article-title":"A phase I trial of high-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma","volume":"23","author":"Mark","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib\u2013melphalan\u2013prednisone, with or without bortezomib\u2013lenalidomide\u2013dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"ref_58","first-page":"26","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"350","author":"Attal","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_60","first-page":"CD004626","article-title":"First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies","volume":"10","author":"Greb","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: Long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","article-title":"Autologous stem cell transplantation in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and impact of a multidisciplinary quality initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood-2018-99-111477","article-title":"The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Results from the IFM\/DFCI 2009 Trial","volume":"132","author":"Roussel","year":"2018","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Corso, A., Mangiacavalli, S., Cocito, F., Pascutto, C., Ferretti, V.V., Pompa, A., Ciampichini, R., Pochintesta, L., and Mantovani, L.G. (2013). Long-term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: A cost-effectiveness analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075047"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/leu.2016.381","article-title":"Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis","volume":"31","author":"Gay","year":"2016","journal-title":"Leuk."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbmt.2014.12.026","article-title":"Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant","volume":"21","author":"Holstein","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000484652","article-title":"Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan","volume":"139","author":"Muta","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: Impact on progression-free and overall survival","volume":"18","author":"Mikhael","year":"2012","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.bbmt.2018.01.035","article-title":"Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"24","author":"Garderet","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ctrv.2008.02.003","article-title":"A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma","volume":"34","author":"Hicks","year":"2008","journal-title":"Cancer Treat Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705339","article-title":"Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma","volume":"37","author":"Sahebi","year":"2006","journal-title":"Bone Marrow Transpl."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65\/ GMMG-HD4 Trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","article-title":"Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Baertsch","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomized, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2019-130644","article-title":"Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial","volume":"134","author":"Vij","year":"2019","journal-title":"Blood"},{"key":"ref_86","unstructured":"ClinicalTrials.gov (2020, December 15). Bethesda (MD): National Library of Medicine (USA). 29 February 2000. Identifier NCT03224507, Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma-MASTER Trial, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03224507."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/bmt.2008.22","article-title":"Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma","volume":"41","author":"Faucher","year":"2008","journal-title":"Bone Marrow Transpl."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma-A retrospective case-matched study from the European Group for Blood and Marrow transplantation","volume":"88","author":"Ljungman","year":"1996","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bmt.1701362","article-title":"Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma","volume":"22","author":"Majolino","year":"1998","journal-title":"Bone Marrow Transpl."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.exphem.2013.08.003","article-title":"Evolving strategies with immunomodulating drugs and tandem autologous\/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Schwerdtfeger","year":"2002","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Sayer","year":"2002","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Sureda","year":"2008","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2008-07-167379","article-title":"Nonmyeloablative allografting for newly diagnosed multiple myeloma: The experience of the Gruppo Italiano Trapianti di Midollo","volume":"113","author":"Bruno","year":"2009","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: A CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: A report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"96","author":"Moreau","year":"2011","journal-title":"Haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Badbaran","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-019-0537-2","article-title":"Allogeneic transplantation in multiple myeloma: Long-term follow-up and cytogenetic subgroup analysis","volume":"33","author":"Knop","year":"2019","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41409-020-0887-4","article-title":"Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation","volume":"55","author":"Costa","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2010.02.015","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma","volume":"16","author":"Efebera","year":"2010","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbmt.2017.10.014","article-title":"Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation","volume":"24","author":"Patriarca","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bbmt.2017.05.006","article-title":"Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis","volume":"23","author":"Castagna","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2014.04.027","article-title":"The graft-versus-myeloma effect: Chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation","volume":"20","author":"Donato","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_116","unstructured":"(2019). S1803, Phase III Study of Daratumumab\/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study), Southwest Oncology Group. NCT04071457."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Zhou, X., Einsele, H., and Danhof, S. (2020). Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072166"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/863\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:25:49Z","timestamp":1760160349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":119,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cancers13040863"],"URL":"https:\/\/doi.org\/10.3390\/cancers13040863","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}